NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 1 FDA
NCT04704934 2026-01-12Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Daiichi SankyoPhase 3 Active not recruiting490 enrolled
NCT04879368 2025-07-17INTEGRATEIIbAustralasian Gastro-Intestinal Trials GroupPhase 3 Active not recruiting450 enrolled
NCT02509286 2024-05-08ESOPECUniversity Hospital Schleswig-HolsteinPhase 3 Active not recruiting438 enrolled